期刊文献+

静注人免疫球蛋白变性后的毒性及作用机理研究 被引量:2

Studying the toxicity and toxic mechanism of intravenous human immunoglobulin after denaturation
原文传递
导出
摘要 目的:研究变性后静注人免疫球蛋白的毒性及致死机理。方法:用静脉注射法分别给小鼠和家兔注射不同来源的人免疫球蛋白样品,观察对2种动物的毒性作用;用硝酸和高温变性人免疫球蛋白查找毒性致死原因,并用血细胞凝集实验研究毒性致死机理。结果:2号样品和变性后的人免疫球蛋白均可通过血细胞凝集,导致心脑缺血而使动物迅速死亡;不同厂家的人免疫球蛋白热稳定性存在差异。结论:变性后的人免疫球蛋白可对动物产生致死性毒性,在日常的运输和保管过程中要注意温度的控制,避免因高温而使人免疫球蛋白药品变性。 Objective:Studying the toxicity and toxic mechanism of intravenous human immunoglobulin(IvIg) after denaturation.Method:Observing toxic effect of IvIg from different sources by intravenous injection to mice and rabbits.Screening the lethal effect of denaturated IvIg by using nitric acid and high temperature.Studying the toxic mechanism by observing hemagglutination test.Result:No.2 and denaturated IvIg samples kill animals fleetly by ischemia in heart and brain induced by hemagglutination.There is difference of heat stability between different IvIg suppliers.Conclusion:Because of denaturated IvIg could produce fatal toxic effect,we should control temperature to avoid temperature degeneration during daily transport and storage.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第2期208-212,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 静注人免疫球蛋白 变性 毒性作用机理 intravenous human immunoglobulin (IvIg) denaturation mechanism of toxicity
  • 相关文献

参考文献6

  • 1Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci ,2002,23 (Suppl) 1 :S1.
  • 2侯麦花,孙凌云,卢新政.静脉注射用免疫球蛋白的应用及其机制[J].中华风湿病学杂志,2004,8(7):433-435. 被引量:8
  • 3ZHOUShun-wu(周顺伍).Animal Biochemistry(动物生物化学).Beijing(北京):China Agnculture Press(中国农业出版社).2002.33.
  • 4ZHOUHai-jun(周海钧).Pharmaceutical Bioassay(药品生物检定).Beijing(北京):People’s Medical Publishing House(人民卫生出版社),2005.517.
  • 5ChP(中国药典).2005.VolⅢ(三部):163.
  • 6刘伟,罗永康,沈小琴,李志超.牛初乳粉中免疫球蛋白热稳定性及热动力学的研究[J].中国乳品工业,2005,33(3):6-9. 被引量:10

二级参考文献17

  • 1车云波.牛初乳功能食品的开发[J].辽宁农业职业技术学院学报,2004,6(2):34-35. 被引量:3
  • 2Bleeker WK,Teeling JL,Erik Hack C.Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect.Blood,2001,98: 3136-3142.
  • 3Hundt M,Manger K,Dorner T,et al.Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin.Rheumatology,2000,39: 1301-1302.
  • 4Emmi L,Chiarini F.The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.Neurol Sci,2002,23 (Suppl) 1 :S 1-8.
  • 5Jordan SC,Tyan D,Czer L,et al.Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients.Pediatr Transplant,1998,2:92-105.
  • 6Sewell WAC,Jolles S.Immunomodulatory action of intravenous immunoglobulin.Immunology,2002,107:387.
  • 7Bayry J,Lacroix-Desmazes S,Carbonneil C,et al.Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.Blood,2003,101: 758-765.
  • 8Yu Z,Lennon VA.Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases.New Engl J Med,1999,340:227-228.
  • 9Spellberg B,Yu Z,Lennon VA.Mechanism of Intravenous Immune Globulin Therapy.New Engl J Med,1999,341:57-58.
  • 10Marinos C,Dalakas MD.Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies.Neurology,2002,59:S13-S21.

共引文献23

同被引文献15

  • 1Koppel H,Schneider B,Watzig H.Out-of-specification Test Results from the Statistical Point of View[J].Journal of Pharmaceutical and Biomedical Analysis,2007,44:718-829.
  • 2CDER,FDA,DHHS.Draft Guidance for Industry:Investigating out of Specification(OOS)Test Results for Pharmaceutical Production.Bethesda Md[S].1998.
  • 3US FDA(2006)Guidance for Industry.Investigating Outof-specification(OOS)Test Results for Pharmaceutical Production[S].2006.
  • 4Brian K.Nunnally,PhD.Deedra F.Nunnally,John S.McConnell.Avoiding the Pain of Out-of-Specification Results(Failing to Apply Iimportant Statistical Principles Ieads to Unnecessary Investigations and Wastes Time and Rresources.Control Charts Can Help) [EB/OL].[2015-03-11].Biopharm International,1 Jun 2008,21 ( 6 ) :http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=522197.
  • 5Tim Sandle.Investigating Sterility Test Failures.Global BioPharmaceutical Resources,Inc.February 2011 GBPR,Inc.Newsletter[S].2011.
  • 6Jenny Hantzinikolas.Laboratory Investigations-A Regulatory Perspective[S].29 July 2008.
  • 7European Compliance Academy.OOS Forum[S].28 August,2014.
  • 8Ilya Kuselman,Francesca Pennecchi,Cathy Burns,et al.Investigating Out-of-Specification Test Results of Chemical Composition Based on Metrological Concepts[J].Accred Qual Assur,2010,15:283-288.
  • 9Vikram Chopra,Anil Kumar Shukla,Ravindran Aiyyer,et al.Investigating Out-of-Specification Results and De v e l o pme nt CAPA Pro g ra m f o r Pha rma ce ut i c a l Industries[J].An Overview,2011,3(2):368-382.
  • 10USP35-NF30[S].2012.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部